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Abstract A number of phosphotyrosine-containing peptides
derived from the PDGF receptor phosphorylation sites have
been synthesised. The peptides were assayed as substrates of the
two isoforms (IF1 and IF2) of the low Mr PTPase. The
calculated kcat, Km, and kcat/Km values indicate that only one
peptide is best hydrolysed by IF2 (but not IF1), whose catalytic
efficiency averages those previously reported for most PTPases
(except the Yersinia enzyme). This peptide is the only one
containing a couple of no bulky hydrophobic residues at the
phosphotyrosine N-side. The determination of the same catalytic
parameters in the presence of analogues of the best hydrolysed
peptide in which one or both hydrophobic residues were replaced
by Asp or Lys residues confirmed the importance of the
hydrophobic cluster at the phosphotyrosine N-side for optimal
enzymatic hydrolysis. These findings are discussed in the light of
the known IF2 X-ray structure.
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1. Introduction
Phosphotyrosine protein phosphatases (PTPases) are a fam-
ily of enzymes catalysing the hydrolysis of phosphotyrosine,
both free and in peptides or proteins [1,2]. Due to their hydro-
lytic activity, PTPases counteract the action of protein tyro-
sine kinases (PTKs), a large group of enzymes involved in a
number of cellular activities and particularly in the control of
cell proliferation and di¡erentiation. The biological impor-
tance of these enzymes is testi¢ed by the fact that some on-
cogenes encode growth factor receptors devoid of the regula-
tory subunits and hence with constitutive PTK activity. Due
to the antiproliferative action of a number of PTPases, the
genes encoding these enzymes have been considered tumour-
suppressing genes or even anti-oncogenes [3].
At present, over 50 enzymes are classi¢ed into the PTPase
family; these enzymes are grouped into several classes with
poor or no homology to each other [4]. All these enzymes
share only a limited sequence motif (CXXXXXRS/T) contain-
ing some of the active site residues (active site signature) and
the catalytic mechanism, which proceeds through a cysteinyl-
phosphate intermediate [5]. A class of PTPases comprises en-
zymes characterised by a reduced molecular mass (low Mr
PTPases) previously known as non-lysosomal acid phospha-
tases (EC 3.1.3.2) [6]. Low Mr PTPases (EC 3.1.3.48) are
present in organisms spanning the entire phylogenetic scale,
from prokaryotes to mammals, where they are likely to per-
form di¡erent functions [7]. In mammals, three alleles (A, B
and C) encoding the enzyme have been described [8]; each
allele expresses two isoforms originating from alternative
splicing [9], which di¡er from each other only in the 40^73
region [7]. These isoforms have been named fast (f) and slow
(s), respectively, on the basis of the di¡ering electrophoretic
mobility or, alternatively, IF1 and IF2.
In 1994, the X-ray structure at 2.1 Aî resolution of the
bovine liver IF2 has been reported [10]. The enzyme is a
closely packed K/L structure in which a central four-stranded
open-twisted L sheet is surrounded on both sides by K helices.
In the structure, the active site signature residues form a
smooth phosphate binding loop (P-cradle) connecting K1 to
L1. This structure di¡ers from that of PTPases belonging to
di¡ering classes [11^13]; however, all these enzymes possess
the same active site residues located at the bottom of a deep
crevice lined by residues which could be involved in the di¡er-
ential kinetic behaviour and substrate preference of the vary-
ing PTPases [14]. Some of these residues are likely to be re-
sponsible for the di¡ering substrate a⁄nity as well as cGMP
and purine sensitivity of IF1 and IF2; this has recently been
con¢rmed by a study performed by using a mutagenesis ap-
proach, which underlined the molecular basis of the di¡ering
IF1 and IF2 behaviour [15].
Despite the structural and kinetic data currently available
on the PTPases, little is known about the substrate speci¢city
or preferences of these enzymes and about the molecular basis
of such speci¢city. The bovine liver IF2 and its dominant
negative mutant (C12S) appear to speci¢cally interact, both
in vitro and in vivo, with the autophosphorylated PDGF re-
ceptor; the low Mr PTPase has also been reported to interact
with the EGF receptor in brain and with the insulin receptor.
The interaction with the wild-type enzyme leads to dephos-
phorylation of these receptors, which hence have been consid-
ered among the true physiological substrates of the enzyme
[16^19].
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The search for good substrates for PTKs and PTPases and
for molecular motifs enhancing enzyme-to-substrate a⁄nity
can take advantage from the use of Tyr-phosphorylated syn-
thetic peptides with sequences both derived from those of
known proteins which physiologically undergo tyrosine phos-
phorylation or modi¢ed [20,21]. IF1 and IF2 exhibit di¡ering
kinetic behaviour on Tyr-phosphorylated peptides derived
from the sequences of varying proteins [22]. In the present
paper, we extend these ¢ndings focusing the analysis on the
main phosphorylation sites of the L-PDGF receptor. We
therefore synthesised Tyr-phosphorylated peptides with se-
quences derived from those of the PDGF receptor main phos-
phorylation sites as well as some peptide derivatives contain-
ing speci¢c amino acid substitutions; the main kinetic
parameters of either low Mr PTPase isoform on each peptide
were then determined. The substrate molecular features which
are likely to ensure optimal hydrolytic activity of either iso-
form are also discussed.
2. Materials and methods
Fmoc-Tyr(PO(OBzl)OH)-OH, side chain unprotected Fmoc-
Tyr(PO3H2)-OH and TGA resins bound to the C-terminal Fmoc-ami-
no acids were from Novabiochem; Fmoc-Tyr(PO3Me2) was from
Bachem; Fmoc-amino acids-OPfp were from Novabiochem or from
Perspective Biosystems; TBTU, HOBt, dimethylformamide, diisopro-
pylcarbodiimide, TFA and piperidine were from Perspective Biosys-
tems. A C18 RP-HPLC column (Vydac) was used for peptide puri¢-
cation. All other reagents and solvents were analytical grade. Peptide
sequences were taken from the SwissProt data bank.
2.1. Synthesis of phosphopeptides
Phosphotyrosine-containing peptides were synthesised in solid
phase using a MilliGen 9050 PepSynthesizer following Fmoc chemis-
try. The NovaSyn TGA resin composed of a polystyrene matrix
grafted with polyethylene oxide functionalised with the 4-hydroxy-
methylphenoxyacetic acid linker bound to the Fmoc-protected C-ter-
minal amino acid was used; resins showed an overall substitution level
of 0.10^0.20 mmol/g, depending on the resin type. Peptide synthesis
was carried out by the standard Fmoc protocol using a fourfold
excess (4 equiv.) of each Fmoc-amino acid OPfp-ester in the presence
of 1 equiv. of HOBt. Fmoc-Tyr(PO(OBzl)OH)-OH or Fmoc-
Tyr(PO3H2)-OH was coupled in DMF containing 0.6 M N-ethylmor-
pholine and 1 equiv. of TBTU; Fmoc-Tyr(PO3Me2)-OH was coupled
with diisopropylcarbodiimide as previously reported [21]. Coupling
cycles of 1 h were used throughout the synthesis; when necessary,
double coupling cycles were performed. Side chain protection was
accomplished by t-butyl ether or ester for Asp, Glu, Ser, Thr and
Tyr, and by the BOC group for Lys and the Trt group for histidine.
Fmoc group deprotection was carried out with 20% piperidine in
DMF. All other steps were performed in DMF. Peptide cleavage
and deprotection were carried out on the dried resin by incubation
for 60^120 min. When using Fmoc-Tyr(PO(OBzl)OH)-OH as a syn-
thon, the deprotection cocktail was TFA/TIS/water (90:5:5); when
using Fmoc-Tyr(PO3H2)-OH, the deprotection cocktail was TFA/thi-
oanisole/anisole/ethanedithiol (90:5:3:2). Finally, when the Fmoc-
Tyr(PO3Me2)-OH synthon was used, peptide cleavage and deprotec-
tion were carried out as previously reported [22]. Deprotection times
and cocktail compositions varied according to the amino acid content
of each peptide. Each crude peptide was precipitated with cold ether,
centrifuged, washed four times with an excess of cold ether and dried
under vacuum. The dry powder of each peptide was resuspended in
10% acetonitrile/water and puri¢ed by semipreparative RP-HPLC on
a C18 Vydac (20U250 mm) column.
2.2. Assessment of peptide purity
Peptide purity was assayed by both amino acid analysis and FAB
mass spectrometry. The former was carried out as previously de-
scribed [23]; the same method was also used to determine peptide
concentrations. Values for serine and threonine were corrected for
loss during hydrolysis. FAB mass spectra were recorded using a VG
Analytical 70-70 EQ instrument as previously reported [24]. Phos-
phate analysis in each synthesised peptide was carried out on samples
of known concentrations by the method of Fiske and Subbarow [25].
2.3. IF1 and IF2 puri¢cation and assay
Low Mr PTPase IF1 and IF2 were puri¢ed from rat liver (where
they are also indicated as AcP1 and AcP2, respectively) as previously
described [26]. PTPase activity was assayed at pH 5.5 using PNPP or
phosphotyrosine as substrates, as previously described [15]. The ki-
netic parameters of either PTPase isoform using each Tyr-phosphory-
lated peptide as a substrate were determined by following phosphate
release by the malachite green assay [22]. Poorly hydrolysed peptides
were incubated for longer times to enhance test sensitivity.
3. Results and discussion
We synthesised a number of Tyr-phosphorylated peptides
whose amino acid sequences were those surrounding the main
phosphorylation sites of the L-PDGF receptor. The synthesis
was carried out using the Fmoc chemistry at the conditions
reported in Section 2. Three di¡ering building blocks were
used to introduce the phosphotyrosine residue in each pep-
tide: Fmoc-Tyr(PO(OBzl)OH)-OH, Fmoc-Tyr(PO3Me2)-OH
and Fmoc-Tyr(PO3H2)-OH. The use of the latter was previ-
ously claimed to give the desired peptides in good yield with-
out side chain modi¢cations during cleavage and deprotection
steps [27]; however, when using this synthon, we got crude
peptides of poor purity, probably due to side reactions during
deprotection. Similarly, the use of the Fmoc-Tyr(PO3Me2)-
OH synthon gave crude peptides of low purity, as previously
reported [22]. Instead, we got good yields of quite pure crude
peptides by using the Fmoc-Tyr(PO(OBzl)OH)-OH synthon
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Table 1
Amino acid sequences of the synthetic Tyr-phosphorylated peptidesa
Peptide Sequence PDGF receptor phosphorylation site
PDGFRP1 H2N-ESVDYVPML-COOH Y751
PDGFRP2 H2N-DSNYISKG-COOH Y857
PDGFRP3 H2N-DGGYMDMSKD-COOH Y740
PDGFRP4 H2N-ESSNYMAPYD-COOH Y771
PDGFRP5 H2N-DGHEYIYVD-COOH Y579
PDGFRP6 H2N-EYIYVDPMQL-COOH Y581
PDGFRP7 H2N-SAELYSNAL-COOH Y716
PDGFRP8 H2N-GDNDYIIPL-COOH Y1021
PDGFRP9 H2N-SVLYTAVQ-COOH Y1009
PDGFRP9LD H2N-SDLYTAVQ-COOH Y1009
PDGFRP9DD H2N-SDDYTAVQ-COOH Y1009
PDGFRP9KK H2N-SKKYTAVQ-COOH Y1009
aPeptides were synthesized by Fmoc chemistry as indicated in Section 3.
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and the deprotection protocol reported in Section 2. The
crude peptides were easily puri¢ed in good ¢nal yields by
RP-HPLC and their purity was checked by amino acid anal-
ysis and FAB mass spectrometry; in addition, the stoichiom-
etry of inorganic phosphate in each peptide was quantitated
by measuring it after combustion or complete enzymic hydrol-
ysis of a known sample of the peptide. All puri¢ed peptides
showed correct amino acid compositions and molecular
masses without any detectable impurity, and contained an
amount of inorganic phosphate corresponding to a peptide/
phosphate ratio of about 1. In particular, the positive FAB
mass spectra of each peptide showed a distinct molecular ion
at an m/z value one unit higher than the calculated molecular
mass of the same peptide. Table 1 reports the amino acid
sequences of the synthesised peptides together with the corre-
spondence of each peptide to the phosphorylation site in the
whole L-PDGF receptor.
Each puri¢ed peptide was used as a substrate for rat liver
IF1 and IF2, whose hydrolytic activities were determined by
the malachite green colorimetric assay in a ¢nal volume of 0.5
ml by comparison with a calibration curve obtained as pre-
viously reported [22]. The test showed a good reproducibility
and a limit of sensitivity lower than 0.5 nmol of inorganic
phosphate, allowing determination of the kinetic parameters
even for those peptides with the highest a⁄nity or the lowest
susceptibility to hydrolysis. By using this assay we determined
the main kinetic parameters as well as the catalytic e⁄ciencies
of IF1 and IF2 in the presence of each synthetic peptide
(Table 2). The following observations can be made: (i) most
peptides are hydrolysed quite slowly and only in the presence
of PDGFRP9 IF2 shows a rate constant higher than 25 s31,
whereas all other peptides are hydrolysed more (or much
more) slowly; (ii) the IF2 kcat in the presence of PDGFRP9
is comparable to those reported for a number of other
PTPases (with the exception of the Yersinia PTPase, which
shows extremely high phosphopeptide dephosphorylation
rates) [20,21,28]; (iii) the apparent Km values indicate that
only PDGFRP9 displays a good a⁄nity for both IF1 and
IF2 (90 and 30 WM, respectively) ; (iv) all other peptides dis-
play low a⁄nities, with apparent Km values that, in some
cases, are over two orders of magnitude higher. Quite low
a⁄nities were also found in an earlier study of the same en-
zymes in the presence of Tyr-phosphorylated peptides derived
from the sequences of a number of proteins undergoing phos-
phorylation on tyrosine [22]. Therefore, PDGFRP9 is the ¢rst
low Mr PTPase substrate for which the enzyme displays an in
vitro a⁄nity comparable to those reported for a number of
other PTPases [20,21,28,29]. The IF1 and IF2 Km/kcat values
in the presence of each phosphorylated peptide are also re-
ported in Table 2. In the presence of PDGFRP9, IF2 shows
the best kinetic e⁄ciency. The latter is about 2^4 orders of
magnitude higher than all others, in particular, it is about two
orders of magnitude higher than the IF1 kinetic e⁄ciency in
the presence of the same peptide, and comparable to the val-
ues reported for a number of other PTPases except the Yersi-
nia enzyme [20,21,28].
Among all synthesised peptides, PDGFRP9 is the only one
containing two hydrophobic residues with no bulky side
chains at positions 31 and 32 with respect to phosphotyro-
sine and no charged residues at both sides of phosphotyrosine.
To check the importance of such features, we synthesised two
analogues of this peptide in which the 32 Val and the 31 Leu
32 Val were replaced by one and two Asp residues, respec-
tively. The kinetic behaviour of either IF1 and IF2 in the
presence of these peptides (named PDGFRP9LD and
PDGFRP9DD, respectively) is reported in Table 2. It can
be seen that the presence of an acidic residue at 32 strongly
impairs IF2 kcat and catalytic e⁄ciency though maintaining
unchanged Km values, whereas the presence of both Asp res-
idues considerably lowers the a⁄nity of either isoform for the
peptide, raising the Km values by about 25 and 100 times,
respectively. The presence, at the phosphotyrosine N-side, of
one or two acidic residues replacing hydrophobic residues
lowers the IF2 catalytic e⁄ciency to values similar to those
found for IF1 and for either isoform in the presence of all
other peptides; this ¢nding indicates the importance of the 31
and 32 positions for substrate recognition and hydrolysis, as
reported for other PTPases [20] ; instead, the presence of Pro
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Table 2
Kinetic behaviour of rat liver IF1 and IF2 on the PDGF-derived
Tyr-phosphorylated peptides either normal or modi¢eda
Peptide kcat (s31) Km (mM) kcat/Km
(s31 M31)U103
IF1 IF2 IF1 IF2 IF1 IF2
PDGFRP1 11.34 13.30 1.58 6.90 7.18 1.93
PDGFRP2 0.12 0.05 0.38 0.36 0.32 0.14
PDGFRP3 13.18 2.85 1.23 1.07 10.72 2.66
PDGFRP4 15.23 14.55 0.60 0.94 25.38 15.48
PDGFRP5 7.05 15.83 1.10 8.49 6.41 3.04
PDGFRP6 4.67 1.40 0.43 0.22 10.86 6.36
PDGFRP7 6.24 4.81 0.90 1.88 6.93 2.56
PDGFRP8 7.14 1.81 0.60 5.54 11.90 0.33
PDGFRP9 0.88 26.32 0.09 0.03 9.78 877.33
PDGFRP9LD 0.24 0.09 0.05 0.04 4.80 2.75
PDGFRP9DD 3.75 1.54 2.14 3.88 1.75 0.40
PDGFRP9KK 6.01 2.47 1.22 3.72 5.46 6.66
aThe values are the average of three determinations.
Fig. 1. Outline of the three-dimensional structure of IF2. The resi-
dues lining the border of the active site crevice are in black. The
catalytic Cys residue at the bottom of the crevice is in grey.
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at +3 (PDGFRP4, PDGFRP6 and PDGFRP8) does not seem
to have any e¡ect. PDGFRP6 was the only other peptide with
two hydrophobic residues at the 31 and 32 positions, how-
ever it was a poor substrate for either isoform. This ¢nding
can be explained considering that the 32 residue in
PDGFRP6 (Tyr) has a more bulky side chain than the corre-
sponding residue in PDGFRP9 (Val) ; in addition, PDGFRP6
contains a charged Asp residue at 33. These features suggest
that position 33 also has importance for optimal substrate
binding and hydrolysis.
The reported results indicate that IF2 is more sensitive than
IF1 to hydrophobic residueCacidic residue substitutions at
the phosphotyrosine N-side in terms of substrate a⁄nity, ki-
netic constant and catalytic e⁄ciency. This result agrees with
previous structural and kinetic ¢ndings indicating that in IF1
and IF2 and other PTPases, the residues lining the hydropho-
bic pocket are important for substrate recognition and bind-
ing as well as for the di¡erential kinetic behaviour [10,14,15].
These residues are mainly basic in PTP1B and Yersinia
PTPase as well as in SH2-domain proteins, thus providing a
possible explanation for the strong preference of a number of
PTPases for substrates containing acidic residues at the phos-
photyrosine N-side [20,29^31]. In IF1 and IF2, these residues
are mainly hydrophobic: L13, I16, Y49 (W49 in IF2), E50
(N50 in IF2), Y131, Y132), thus providing a molecular basis
for the strong preference of these enzymes for substrates con-
taining hydrophobic residues at the key 31 and 32 positions
in terms of either a⁄nity (IF1) or catalytic e⁄ciency (IF2)
(Fig. 1). In particular, residues at positions 49 and 50 have
been shown to be important for IF1 and IF2 di¡erential sub-
strate preference, kinetic behaviour and purine nucleotide ac-
tivation [15]. This ¢nding could explain the strong IF2 pref-
erence for PDGFRP9 respect to IF1; in fact, IF1 contains an
acidic residue (E50) which could account for its remarkably
lower catalytic e⁄ciency on the same peptide.
The importance of position 50 for peptide recognition by
either isoform was con¢rmed by synthesising a PDGFRP9
derivative in which two Lys residues were present at the 31
and 32 positions (PDGFRPKK). Table 2 reports the kinetic
behaviour of IF1 and IF2 in the presence of this peptide. It
can be seen that IF2 behaves as it does in the presence of
PDGFRPDD, whereas IF1 shows only a slight rise in cata-
lytic e⁄ciency, whose value becomes similar to that measured
in the presence of the PDGFRP9 peptide due to an increase of
the kcat value.
From our data, it can be concluded that, apparently,
PDGFRP9 is the best substrate for IF2 whereas, among all
synthesised peptides, no one appears a good substrate for IF1,
suggesting that IF1 and IF2 act on di¡erent physiological
substrates; in fact, IF2 best hydrolyses peptides containing
hydrophobic residues at the phosphotyrosine N-side whereas,
from our study, it is not possible to assess which are the
substrate molecular features allowing optimal phosphopeptide
hydrolysis by IF1. The remarkable preference of IF2 for
PDGFRP9 does not necessarily mean that Tyr-1009, the
PDGF receptor phosphorylation site corresponding to this
peptide, is the preferential site of interaction of this enzyme
isoform with the receptor; rather this ¢nding indicates that
the enzyme preferential substrate(s) should possess a recogni-
tion motif in which an important role is performed by hydro-
phobic residues at the phosphotyrosine N-side, thus providing
an useful information in the search of the enzyme physiolog-
ical substrate(s).
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